SK-BR-3

SK-BR-3是在1970年由紀念斯隆-凱特琳癌症中心的科研人員分離的人類乳癌細胞系，目前應用於乳癌治療方案的研究，尤其是在靶向HER2/neu的研究^[1]。

特徵

SK-BR-3細胞與AU565細胞分離自同一名曾接受過放射及5-氟尿嘧啶等治療的患者^[2]。SK-BR-3細胞源自於一名43歲白人女性患者體內，由乳癌引起的胸腔積液^[1]，並且過度表達著HER2/neu產物，而該產物被認為與多種乳癌增殖的途徑有關。SK-BR-3細胞已知會以葡萄狀簇（grape-like clusters）的形式生長，其侵襲性表型與體內細胞類似^[3]。

科研用途

SK-BR-3細胞已用於尋求能克服曲妥珠單抗對乳腺癌（過度表達人類表皮生長因子受體2）的抵抗力的研究^[4]。而且有科研人員已經檢查了該細胞系在CRISPR/Cas9基因編輯與轉染中的抗體抗性^[5]，以及在微環境存在波動的情況下，基於HER2/neu的癌症治療中的應用^[6]。

參考資料

^ ^1.0 ^1.1 SK-BR-3: Human Breast Cancer Cell Line (ATCC HTB-30). Memorial Sloan-Kettering Cancer Center. [2018-06-18]. （原始內容存檔於2018-06-18）.
^ SK-BR-3 cells. Addex Bio. [2018-06-18]. （原始內容存檔於2018-06-19）.
^ Holliday, DL; Speirs, V. Choosing the right cell line for breast cancer research.. Breast cancer research : BCR. 2011-08-12, 13 (4): 215 [2020-01-05]. PMID 21884641. doi:10.1186/bcr2889. ^{[永久失效連結]}
^ Tseng, PH; Wang, YC; Weng, SC; Weng, JR; Chen, CS; Brueggemeier, RW; Shapiro, CL; Chen, CY; Dunn, SE; Pollak, M; Chen, CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.. Molecular pharmacology. 2006-11, 70 (5): 1534–41 [2020-01-05]. PMID 16887935. doi:10.1124/mol.106.023911. ^{[永久失效連結]}
^ Cao, J; Wu, L; Zhang, SM; Lu, M; Cheung, WK; Cai, W; Gale, M; Xu, Q; Yan, Q. An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.. Nucleic acids research. 2016-11-02, 44 (19): e149 [2020-01-05]. PMID 27458201. doi:10.1093/nar/gkw660. ^{[永久失效連結]}
^ Weigelt, B; Lo, AT; Park, CC; Gray, JW; Bissell, MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.. Breast cancer research and treatment. 2010-07, 122 (1): 35–43 [2020-01-05]. PMID 19701706. doi:10.1007/s10549-009-0502-2. ^{[永久失效連結]}

外部連結

Cellosaurus entry for SK-BR-3（頁面存檔備份，存於網際網路檔案館）

[MSKCC-1] 1.0 ^1.1 SK-BR-3: Human Breast Cancer Cell Line (ATCC HTB-30). Memorial Sloan-Kettering Cancer Center. [2018-06-18]. （原始內容存檔於2018-06-18）.

[2] SK-BR-3 cells. Addex Bio. [2018-06-18]. （原始內容存檔於2018-06-19）.

[3] Holliday, DL; Speirs, V. Choosing the right cell line for breast cancer research.. Breast cancer research : BCR. 2011-08-12, 13 (4): 215 [2020-01-05]. PMID 21884641. doi:10.1186/bcr2889. ^{[永久失效連結]}

[4] Tseng, PH; Wang, YC; Weng, SC; Weng, JR; Chen, CS; Brueggemeier, RW; Shapiro, CL; Chen, CY; Dunn, SE; Pollak, M; Chen, CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.. Molecular pharmacology. 2006-11, 70 (5): 1534–41 [2020-01-05]. PMID 16887935. doi:10.1124/mol.106.023911. ^{[永久失效連結]}

[5] Cao, J; Wu, L; Zhang, SM; Lu, M; Cheung, WK; Cai, W; Gale, M; Xu, Q; Yan, Q. An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.. Nucleic acids research. 2016-11-02, 44 (19): e149 [2020-01-05]. PMID 27458201. doi:10.1093/nar/gkw660. ^{[永久失效連結]}

[6] Weigelt, B; Lo, AT; Park, CC; Gray, JW; Bissell, MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.. Breast cancer research and treatment. 2010-07, 122 (1): 35–43 [2020-01-05]. PMID 19701706. doi:10.1007/s10549-009-0502-2. ^{[永久失效連結]}

[1]

[2]

[3]

[4]

[5]

[6]